logo-loader

Stellar Biotechnologies shareholders approve reverse merger with Edesa Biotech; shares spike

Last updated: 15:10 31 May 2019 EDT, First published: 14:48 31 May 2019 EDT

biotech
Stellar develops therapies to treat Alzheimer's, lupus and cancer

Shares of Stellar Biotechnologies Inc (NASDAQ:SBOT) spiked Friday a day after the company said in a regulatory filing that its shareholders have approved a reverse merger with Edesa Biotech Inc.

The deal was originally announced in March. Under the terms, Edesa shareholders have agreed to exchange their shares for newly issued shares of Stellar and will own about 90% of the new company. Stellar shareholders will hold the remainder.

Stellar’s stock recently traded up 68% to $2.02 a share on heavy volume.

READ: Stellar Biotechnologies in reverse merger with Edesa Biotech; shares shoot higher

The reverse merger, also called a share-exchange agreement, is expected to close in June. Stellar will change its name to Edesa Biotech Inc.

But Edesa, a private Canadian company based in Toronto, will become a wholly owned subsidiary of Stellar.

Stellar shareholders approved the deal on Thursday, according to Stellar’s Form 8-K filing with the US Securities and Exchange Commission.

Based near Los Angeles, Stellar is a manufacturer of KLH, keyhole limpet hemocyanin, a key immune-stimulating protein used in multiple immunotherapy development pipelines targeting Alzheimer's, lupus and cancer.

Edesa is a clinical stage company that has developed EBO1, a non-steroidal anti-inflammatory molecule for the treatment of allergic contact dermatitis.

Contact the author: patrick@proactiveinvestors.com

Follow him on Twitter @PatrickMGraham

BenevolentAI advances novel ulcerative colitis treatment through Phase 1a trial

BenevolentAI (OTC:BAIVF) chief scientific officer Dr Anne Phelan joins Proactive's Stephen Gunnion with positive safety data from the Phase 1a, first-in-human, clinical study of BEN-8744 in healthy volunteers. Phelan explained that BEN-8744 is a potent, selective PD10 inhibitor, uniquely...

45 minutes ago